Skip to content

Hemab Therapeutics’ Statement Announcing the Planned Departure of Co-Founder and CTO Johan Faber

COPENHAGEN, Demark and BOSTON, March 1, 2023

Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today issued the following statement announcing the planned departure of Co-Founder and Chief Technology Officer Johan Faber, PhD, MSc, effective March 1, 2023:

“Johan Faber, PhD, MSc, was instrumental in the founding of Hemab in 2019 and as the founding CEO of the Company. Since July 2021, he has served as Chief Technology Officer. He brought to the company deep expertise in the biology of clotting as well as 14 years of experience in drug discovery and biopharmaceutical development at Novo Nordisk, including signification contributions to Novoeight®, Esperoct®, Mim8®. He is also a co-inventor of Hemab’s HMB-001 program.

‘Johan’s devoted leadership has helped shape Hemab into the company it is today, and I couldn’t be more grateful for his many contributions,’ said Benny Sorensen, MD, CEO & President of Hemab. ‘His wisdom and pioneering spirit will remain deeply ingrained in the organization as we evolve on our journey to becoming the ultimate clotting company. He is tireless in his pursuits to diligently follow the science toward creating companies and medicines that improve lives, and we are thrilled to follow his next steps.’

‘I am extremely proud of what we have built together at Hemab,’ said Johan. ‘This incredible team has centered patients with high unmet need in our work at every step. I have no doubt they will be successful in their mission to deliver targeted, preventative therapies for people with severe bleeding and thrombotic disorders who have been awaiting innovation for far too long. I look forward to their continued clinical and company success.’”

About Hemab Therapeutics

Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in the US and Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5TM, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with Factor VII Deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and other serious disorders. Learn more at  


Media Contact
Lia Dangelico

Source: Hemab Therapeutics